Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6273818 | 0.84 | ALDH1A1 (0.36) | ALDH1A1PDPK1PI4KAPI4K2BPI4K2A | |
| SCHEMBL21275549 | 0.82 | PDPK1 (0.32) | ALDH1A1PDPK1CHEK1AURKARET | |
| SCHEMBL4938648 | 0.81 | CYP1A2 (0.37) | ALDH1A1PDPK1CHEK1AURKARET | |
| SCHEMBL3433360 | 0.79 | RET (0.31) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL479506 | 0.76 | LMNA (0.46) | ALDH1A1LMNA | |
| SCHEMBL1496187 | 0.75 | PRMT5 (0.34) | ALDH1A1RETPI4KAXDHLRRK2 | |
| SCHEMBL2619222 | 0.75 | PDPK1 (0.36) | ALDH1A1PDPK1CHEK1AURKARET | |
| SCHEMBL30034235 | 0.75 | PDPK1 (0.36) | ALDH1A1PDPK1CHEK1AURKARET | |
| SCHEMBL31001140 | 0.74 | RET (0.52) | PDPK1CHEK1AURKARETPI4KA | |
| SCHEMBL1321549 | 0.74 | RET (0.52) | PDPK1CHEK1AURKARETPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2014194127-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| EP-2524918-A1 | Imidazopyrazines derivates as kinase inhibitors | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-11-21 | — | — | EP | disclosed |
| WO-2012052745-A1 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| WO-2010119264-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010007114-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007116-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | ALDH1A1 3902/4885PDPK1 294/4885CHEK1 140/4885 |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | ALDH1A1 4305/4885PDPK1 25/4885CHEK1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.